Stephanie Gasking 2025 Joint Meeting of the COSA ASM and IPOS Congress

Abstracts this author is presenting:

• Tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) from the VISION study: ≥3-year follow-up outcomes — Afternoon tea, Poster session 1 & Exhibition
• Safety and patient-reported outcomes with tepotinib in patients with METex14 skipping NSCLC: ≥3-year follow-up of VISION — Afternoon tea, Poster session 1 & Exhibition
• Long-term outcomes with tepotinib for clinically relevant subgroups of patients with MET exon 14 (METex14) skipping NSCLC in the VISION study: A ≥3-year follow-up — Afternoon tea, Poster session 1 & Exhibition
• Treatment sequencing of tepotinib in patients with MET exon 14 (METex14) skipping non-small lung cancer (NSCLC): Outcomes from ≥3 years follow-up of the VISION study — Afternoon tea, Poster session 1 & Exhibition